Assign Clinical Research GmbH Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Vienna Austria (2002)
Status: Acquired by Celerion (2016)

Organization Overview

First Clinical Trial
2009
NCT01259518
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Assign Data Management and Biostatistics GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Hemolytic (Phase 1)

Anemia, Hemolytic, Autoimmune (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Chikungunya Fever (Phase 2)

Colorectal Neoplasms (Phase 2)

Disease Progression (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 3)

Gastrointestinal Neoplasms (Phase 2)

Infections (Phase 1)

Kidney Failure, Chronic (Phase 1)

Lassa Fever (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neoplasms, Squamous Cell (Phase 3)

Neuroendocrine Tumors (Phase 2)

Pemphigoid, Bullous (Phase 1)

Sarcoma (Phase 1)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 19